CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,200 enrolled
Drug / intervention
Anticoagulation Agents +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03761173
NCT03761173N/ACompleted

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (FLASH)

Inari Medical·observational·Posted Dec 3, 2018·Updated Oct 1, 2025

In Brief

An observational study evaluating FlowTriever System and Anticoagulation Agents for PE - Pulmonary Embolism and PE - Pulmonary Thromboembolism. Completed, enrolled 1,200 participants across 81 sites in 9 countries.

Detailed Summary

To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE). The use of the device will be assessed in a real-world population, with eligibility criteria that closely approximate its use in clinical practice. Up to 300 additional patients with anticoagulation treatment as the initial planned primary treatment strategy for intermediate risk PE will also be evaluated (US only).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Belgium, France, Germany, Netherlands, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedDec 3, 2018
Enrollment StartDec 15, 2018
Primary CompletionSep 4, 2024
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 7.6 years ago

Interventions

FlowTriever Systemdevice

Thrombectomy

Anticoagulation Agentsdrug

Anticoagulation medication